Panmure Gordon Analyst Dr Mike Mitchell said today “This morning Allergy Therapeutics has announced it has completed patient enrolment for its Phase IIb dose-finding study, G204, in the US. GrassMATAMPL is the company’s programme for Pollinex Quattro Grass in the US (an ultra-short course SCIT, subcutaneous allergen specific immunotherapy) and total patient enrolment for the Phase IIb study was 250 patients. Headline data for the G204 study are expected at the end of the first half of 2016, paving the way for the US Phase III study”
Campaign launched to prevent food allergy-related deaths and illness on Teesside
A new campaign has been launched with the aim of preventing food allergy-related illness and deaths across Teesside. Targeted at restaurants and food outlets, all 12 local authorities in the North East have joined forces to